The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy? In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile. Support the show